Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 7.000

-0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (74)	6/10/2004 12:18:47 AM
From: Jibacoa	Read Replies (1) of 802

Zeta: Ian already answered your question about RAGL.<g> ( I have been running a few "scans" and watching TV and had not checked messages.) Re: The "hemorrhaging in INGN..." lets hope that it will find support above the $5 level. You may remember that in June last year after the first spike to the $10.16 level, the correction the following week brought the price down to $4.80 It then found support at the $5 to $5.30 level and was able to rally to the $11.24 level by mid-September. bigcharts.marketwatch.com INGN has been having pretty good announcements and I still hope that their Advexin and INGN-241 will eventually be approved, but it seems that in spite of the fact that Advexin has received FDA "Fast Track" designation and has been designated as an Orphan Drug under the Orphan Drug Act for head and neck cancer,it will be some time before we see the results of the present PIIIs going on. The estimated loss for the current fiscal year is around $25M and $24.45M for 2005.INGN reportedly has around $30.74M in cash (about $1.16/share)and will need some cash infusion in the near future. RAGL Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next